Zivo Bioscience, Inc.
ZIVO
$17.76
$1.7611.00%
OTC PK
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | 662.71% | 166.95% | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 662.71% | 166.95% | -- | -- | -- |
Cost of Revenue | 718.18% | 187.01% | -- | -- | -- |
Gross Profit | 558.54% | 131.71% | -- | -- | -- |
SG&A Expenses | -13.12% | 43.31% | 331.54% | -37.80% | -25.02% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | -11.63% | 44.65% | 350.22% | -33.43% | -27.65% |
Operating Income | 15.83% | -43.73% | -351.21% | 35.25% | 28.10% |
Income Before Tax | 16.09% | -24.31% | -297.78% | 35.20% | 27.73% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | 16.09% | -24.31% | -297.78% | 35.20% | 27.73% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 16.09% | -24.31% | -297.78% | 35.20% | 27.73% |
EBIT | 15.83% | -43.73% | -351.21% | 35.25% | 28.10% |
EBITDA | -- | -- | -- | -- | -- |
EPS Basic | 54.37% | 36.73% | -110.86% | 62.99% | 41.13% |
Normalized Basic EPS | 54.37% | 36.74% | -110.87% | 62.99% | 41.13% |
EPS Diluted | 54.37% | 36.73% | -110.86% | 62.99% | 41.13% |
Normalized Diluted EPS | 54.37% | 36.74% | -110.87% | 62.99% | 41.13% |
Average Basic Shares Outstanding | 83.88% | 96.46% | 88.65% | 75.06% | 22.78% |
Average Diluted Shares Outstanding | 83.88% | 96.46% | 88.65% | 75.06% | 22.78% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |